Pneumocystis jirovecii Pneumonia Prophylaxis for Cancer Patients during Chemotherapy

被引：14

作者：

Takeuchi, Kazuto ^{[1
]}

Yakushijin, Yoshihiro ^{[1
,2
]}

机构：

[1] Ehime Univ Hosp, Ctr Canc, Toon, Ehime 7910295, Japan

[2] Ehime Univ, Dept Clin Oncol, Grad Sch Med, Toon, Ehime 7910295, Japan

来源：

PATHOGENS | 2021年 / 10卷 / 02期

关键词：

Pneumocystis jirovecii pneumonia (PJP); cancer chemotherapy; prophylaxis; smoking; INFECTIONS;

D O I：

10.3390/pathogens10020237

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Pneumocystis jirovecii pneumonia (PJP) is one type of life-threatening pneumonia in immunocompromised patients. PJP development should be considered in not only immunocompromised individuals, but also patients undergoing intensive chemotherapies and immunotherapies, organ transplantation, or corticosteroid treatment. Past studies have described the clinical manifestation of PJP in patients during chemotherapy and reported that PJP affects cancer treatment outcomes. Therefore, PJP could be a potential problem for the management of cancer patients during chemotherapy, and PJP prophylaxis would be important during cancer treatment. This review discusses PJ colonization in outpatients during cancer chemotherapy, as well as in healthy individuals, and provides an update on PJP prophylaxis for cancer patients during chemotherapy.

引用

页码：1 / 7

页数：6

共 17 条

[1]

[Anonymous], 2014, COCHRANE DB SYST REV

[2] Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014 [J].

Cooley, L. ;

Dendle, C. ;

Wolf, J. ;

Teh, B. W. ;

Chen, S. C. ;

Boutlis, C. ;

Thursky, K. A. .

INTERNAL MEDICINE JOURNAL, 2014, 44 (12B) :1350-1363

[3] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4) [J].

Drgona, L. ;

Gudiol, C. ;

Lanini, S. ;

Salzberger, B. ;

Ippolito, G. ;

Mikulska, M. .

CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 :S83-S94

[4] Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients:: Systematic review and meta-analysis of randomized controlled trials [J].

Green, Hefziba ;

Paul, Mical ;

Vidal, Liat ;

Leibovici, Leonard .

MAYO CLINIC PROCEEDINGS, 2007, 82 (09) :1052-1059

[5] SUCCESSFUL CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONITIS [J].

HUGHES, WT ;

KUHN, S ;

CHAUDHARY, S ;

FELDMAN, S ;

VERZOSA, M ;

AUR, RJA ;

PRATT, C ;

GEORGE, SL .

NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (26) :1419-1426

[6] Infections associated with steroid use [J].

Klein, NC ;

Go, CHU ;

Cunha, BA .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2001, 15 (02) :423-+

[7] Pneumocystis Pneumonia in Solid Organ Transplantation [J].

Martin, S. I. ;

Fishman, J. A. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 :272-279

[8] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52) [J].

Mikulska, M. ;

Lanini, S. ;

Gudiol, C. ;

Drgona, L. ;

Ippolito, G. ;

Fernandez-Ruiz, M. ;

Salzberger, B. .

CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 :S71-S82

[9]

National Comprehensive Cancer Network, 2020, NCCN CLIN PRACTICE G

[10] METABOLIC AND SYNTHETIC ACTIVITIES OF PNEUMOCYSTIS-CARINII INVITRO [J].

PESANTI, EL ;

COX, C .

INFECTION AND IMMUNITY, 1981, 34 (03) :908-914

← 1 2 →